OakChart

Nuvation Bio Inc

NUVBHealthcare·Biotechnology·USA·Small·NYSE·Nov 11 • 3:59 PM ET

4.29+0.09 (2.14%)
2026-11-12 05:40 CET
Market cap
1,518.74 USD m
Revenue, TTM
201.73 USD m
Net income, TTM
-135.93 USD m
Free cash flow, TTM
-108.17 USD m
EPS diluted, TTM
-0.39
P/E
-
Compare

Price

NUVB against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.007.0017.6M35.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NUVBclose 4.2920-day 4.5550-day 5.24200-day 5.344.2952w low

56.0% under the 52-week high of 9.75 on 22 Dec 2025. 52-week low 3.98 on 6 Nov 2026. Last 15 sessions, 23.5% high to low

Volume 0.55× normal · the line is the 50-bar volume average

Profile

NUVB
52-week range, 6% of the way up
3.979.75

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

IndexRUT
Employees298
IPOAug 26, 2020
Beta1.75
ATR, 14d0.28
Rel volume0.55
Short float24.47%
Insider own28.44%
Inst own56.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.52B
Enterprise Value1.32B
Income-135.93M
Sales201.73M
Book/sh0.65
Cash/sh1.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees298
IPOAug 26, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S7.53
P/B6.64
P/C2.29
P/FCF-
EV/EBITDA-
EV/Sales6.56
Quick Ratio7.30
Current Ratio7.45
Debt/Eq2.05
LT Debt/Eq1.95
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.39
EPS next Y-0.27
EPS next Q-0.12
EPS this Y33.00%
EPS next Y32.30%
EPS next 5Y75.31%
EPS past 3/5Y-7.61% -7.00%
Sales past 3/5Y- -
EPS Y/Y TTM39.07%
Sales Y/Y TTM654.19%
EPS Q/Q26.93%
Sales Q/Q242.61%
EarningsNov 04 AMC
EPS/Sales Surpr.2.99% 30.66%

Ownership

Insider Own28.44%
Insider Trans-0.31%
Inst Own56.70%
Inst Trans5.88%
ROA-19.70%
ROE-49.09%
ROIC-20.19%
Gross Margin84.70%
Oper. Margin-61.17%
Profit Margin-67.38%
SMA20-5.66%
SMA50-18.19%
SMA200-19.66%
Trades-

Technical

Shs Outstand351.92M
Shs Float253.34M
Short Float24.47%
Short Ratio11.59
Short Interest62.00M
52W High9.75 -56.00%
52W Low3.97 7.92%
Volatility8.49% 5.93%
ATR (14)0.28
RSI (14)37.93
Beta1.75
Rel Volume0.55
Avg Volume5.35M
Volume2,952,026

Performance

Perf Week-9.30%
Perf Month-9.11%
Perf Quarter-29.67%
Perf Half Y-10.25%
Perf YTD-52.12%
Perf Year-13.86%
Perf 3Y232.56%
Perf 5Y-52.86%
Perf 10Y-
Recom1.15
Target Price12.45
Prev Close4.20
Price4.29
Change %2.14%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 30, 2026InitiatedCCitigroupBuy$12+179.7%
Aug 21, 2026InitiatedCCantor FitzgeraldOverweight
Aug 18, 2026InitiatedJJP MorganOverweight$13+203.0%
Nov 24, 2025InitiatedTTruistBuy
Nov 19, 2025InitiatedRB. Riley SecuritiesBuy$12+179.7%
Sep 30, 2025InitiatedJJefferiesBuy$10+133.1%
Apr 23, 2025InitiatedCCitizens JMPMkt Outperform$6+39.9%
Mar 27, 2024UpgradeJJefferiesHold → Buy$1.40 → $10+133.1%
Mar 26, 2024UpgradeBBTIG ResearchNeutral → Buy$5+16.6%
Jan 06, 2023DowngradeJJefferiesBuy → Hold$5 → $2-53.4%

Peers

Mkt cap
TickerCompanyMkt cap
SNDXSyndax Pharmaceuticals Inc863.37M
CGEMCullinan Therapeutics Inc730.42M
ORICORIC Pharmaceuticals Inc932.88M
VSTMVerastem Inc1.15B
RCUSArcus Biosciences Inc2.71B
TNGXTango Therapeutics Inc4.36B
BMYBristol-Myers Squibb Co128.59B
BDTXBlack Diamond Therapeutics Inc92.50M
IOVAIovance Biotherapeutics Inc3.74B
PFEPfizer Inc167.86B

Insider trading

latest 14 of 47
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hattersley GaryCHIEF SCIENTIFIC OFFICERAug 19 '26Option Exercise1.87100,000187,000100,000Aug 21 04:49 PM
Hattersley GaryCHIEF SCIENTIFIC OFFICERAug 19 '26Sale7.09100,000709,2400Aug 21 04:49 PM
GARY HATTERSLEYOfficerAug 19 '26Proposed Sale6.96100,000696,000Aug 19 04:30 PM
Sauvage PhilippeChief Financial OfficerJul 15 '26Option Exercise2.1740,00086,80054,131Jul 17 06:27 PM
Markel StacyCHIEF PEOPLE OFFICERJun 23 '26Option Exercise1.83125,000229,249157,591Jun 24 07:09 PM
Markel StacyCHIEF PEOPLE OFFICERJun 23 '26Sale6.03125,000753,18832,591Jun 24 07:09 PM
Wentworth KerryCHIEF REGULATORY OFFICERJun 23 '26Option Exercise2.9363,000184,590116,000Jun 24 07:07 PM
Wentworth KerryCHIEF REGULATORY OFFICERJun 23 '26Sale6.0263,000379,19153,000Jun 24 07:07 PM
Sauvage PhilippeChief Financial OfficerJun 23 '26Option Exercise2.1747,668103,44060,341Jun 24 07:07 PM
Sauvage PhilippeChief Financial OfficerJun 23 '26Sale6.0147,668286,37012,673Jun 24 07:07 PM
STACY MARKELOfficerJun 23 '26Proposed Sale5.76125,000720,000Jun 23 04:28 PM
KERRY WENTWORTHOfficerJun 23 '26Proposed Sale5.7663,000362,880Jun 23 04:28 PM
PHILIPPE SAUVAGEOfficerJun 23 '26Proposed Sale5.7647,668274,568Jun 23 04:27 PM
Mashal RobertDirectorJun 09 '26Buy4.7325,000118,250225,000Jun 11 08:02 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
  • Nuvation Bio Beats On Revenue, Misses On EPS As Ibtrozi's First-Line Momentum Stalls (Earnings Whispers) -11.42%
  • Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting (PR Newswire)
  • Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries (PR Newswire)
  • Nuvation Bio's First-Line Ibtrozi Bet Faces A Skeptical Market After A 25% Slide (Earnings Whispers)
  • Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 (PR Newswire)
  • Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer (PR Newswire) +5.02%
  • Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer (PR Newswire)
  • Nuvation Bio to Participate in Upcoming Investor Conferences (PR Newswire)
  • Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma (PR Newswire) -5.92%
  • Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (PR Newswire)
  • Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.120-0.124-0.12044.9534.4013
2026Q22026-08-06-0.180-0.142-0.18031.6927.039
2026Q12026-05-040.010-0.0280.01483.2366.2210
2025Q42026-03-02-0.110-0.089-0.10641.8737.8111
2025Q32025-11-03-0.160-0.169-0.16313.126.618
2025Q22025-08-07-0.170-0.170-0.1734.830.427
2025Q12025-05-07-0.160-0.150-0.1573.080.507
2024Q42025-03-06-0.150-0.128-0.1475.710.006
2024Q32024-11-06-0.150-0.126-0.1510.730.005
2024Q22024-08-05-1.890-0.059-1.8901.440.006
2024Q12024-05-14-0.070-0.092-0.0680.000.006
2023Q42024-02-29-0.060-0.099-0.0630.000.006
2023Q32023-11-02-0.090-0.105-0.0900.000.006
2023Q22023-08-03-0.090-0.112-0.0940.000.006
2023Q12023-05-04-0.100-0.100-0.0990.000.006
2022Q42023-03-15-0.100-0.119-0.0950.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.194-0.169-0.4270.000.00
2021FY-0.440-0.411-0.4390.000.00
2022FY-0.480-0.493-0.4810.000.00
2023FY-0.350-0.372-0.3460.000.00
2024FY-2.110-2.120-2.1137.872.17
2025FY-0.600-0.587-0.60062.9058.86
2026FY--0.402--203.17
2027FY--0.272--250.89
2028FY--0.009--405.05
2029FY--0.017--500.94
2030FY-0.492--749.55

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06132943.2730.8075.93
2026Q4S2026-11-05132843.7230.8075.93
2026Q4S2026-11-04131345.2533.4269.09
2026Q4S2026-10-20131345.2633.4269.09
2026Q4S2026-10-16132746.2333.4269.09
2026Q4S2026-10-09131845.7733.4269.09
2026Q4S2026-10-02131846.0933.4269.09
2026Q4S2026-09-30131846.9433.4269.09
2026Q4S2026-09-15121846.5633.4269.09
2026Q4S2026-09-11121748.5033.4269.09
2026Q4S2026-08-20121848.5033.4269.09
2026Q4S2026-08-17111849.4333.4269.09
2026Q4S2026-08-06101849.8733.4269.09
2026Q4S2026-07-3092154.9647.5066.00

Estimate history

EPS, annual-0.427-0.439-0.481-0.346-2.113-0.599-0.3912
Period202020212022202320242025TTM
EPS, quarterly-0.151-0.147-0.157-0.173-0.163-0.1060.014-0.18-0.119
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00007.87362.902201.73
Period202020212022202320242025TTM
Sales, quarterly0.7275.7113.0844.83313.1241.86583.22831.68744.951
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual149.042217.949218.633219.046337.838337.838352.924
Period202020212022202320242025MRQ
Shares, quarterly336.249337.838339.84337.838342.756337.838346.504349.822352.924
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue201.7362.907.870.000.000.000.00
Cost of Goods Sold Incl. D&A30.8611.047.760.220.480.370.10
Gross Profit170.8751.870.11-0.22-0.48-0.37-0.10
Selling, General and Administrative Excl. Other294.27264.93167.6799.60119.2592.9543.45
Research and Development132.68115.1199.1271.2987.8169.0432.60
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-123.40-213.06-167.56-99.82-119.73-93.32-43.55
Interest Expense26.2613.680.340.000.000.000.00
Unusual Expense7.730.81426.01-0.50-10.19-4.230.00
Net Income Before Taxes-135.93-204.63-567.94-75.80-104.20-86.85-41.66
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-135.93-204.63-567.94-75.80-104.20-86.85-41.66
Net Income From Continuing Operations-135.93-204.63-567.94-75.80-104.20-86.85-41.66
Net Income-135.93-204.63-567.94-75.80-104.20-86.85-41.66
EPS (Recurring)-0.37-0.60-1.00-0.35-0.51-0.45-0.43
EPS (Basic, Before Extraordinaries)-0.39-0.60-2.11-0.35-0.48-0.44-0.43
EPS (Diluted)-0.39-0.60-2.11-0.35-0.48-0.44-0.43
EBITDA-121.21-211.32-166.87-99.60-119.25-92.95-43.45
Non-Operating Income (Expense)21.4622.9325.9623.525.352.241.89
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense37.5535.8932.2719.5116.299.27-
Price To Sales Ratio9.7748.6590.81----
Gross Margin84.7082.451.42----
Operating Margin-61.17-338.72-2,128.25----
Net Margin-67.38-325.31-7,213.76----
Shares Outstanding352.92337.84337.84219.05218.63217.95149.04
Market Capitalization1,518.741,518.74897.93332.12419.311,859.45215.94

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue44.9531.6983.2341.8713.124.833.085.71
Cost of Goods Sold Incl. D&A12.5110.016.531.823.882.932.404.43
Gross Profit32.4421.6876.7040.059.241.900.681.28
Selling, General and Administrative Excl. Other74.6572.7272.8274.0865.6765.4959.6855.22
Research and Development32.6830.6635.0534.3028.8527.3624.6029.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-42.21-51.043.88-34.04-56.43-63.59-59.00-53.94
Interest Expense6.126.766.716.676.530.420.050.09
Unusual Expense0.009.47-2.871.13-0.61-0.450.751.15
Net Income Before Taxes-41.90-62.845.40-36.59-55.79-59.01-53.24-49.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-41.90-62.845.40-36.59-55.79-59.01-53.24-49.45
Net Income From Continuing Operations-41.90-62.845.40-36.59-55.79-59.01-53.24-49.45
Net Income-41.90-62.845.40-36.59-55.79-59.01-53.24-49.45
EPS (Recurring)-0.12-0.160.01-0.10-0.16-0.17-0.16-0.14
EPS (Basic, Before Extraordinaries)-0.12-0.180.02-0.11-0.16-0.17-0.16-0.15
EPS (Diluted)-0.12-0.180.01-0.11-0.16-0.17-0.16-0.15
EBITDA-41.63-50.504.42-33.50-55.90-63.23-58.69-53.72
Non-Operating Income (Expense)6.434.435.365.256.564.556.575.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.0710.469.037.998.0212.037.8510.19
Price To Sales Ratio9.7711.6611.3249.0547.3646.2954.39113.84
Gross Margin72.1868.4292.1695.6670.4039.3322.0522.34
Operating Margin-93.90-161.064.66-81.30-430.14-1,315.73-1,913.23-944.53
Net Margin-93.21-198.316.48-87.40-425.24-1,220.92-1,726.20-865.79
Shares Outstanding352.92349.82346.50337.84342.76337.84339.84337.84
Market Capitalization1,518.741,983.471,491.193,080.741,270.11663.51596.08897.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments529.21502.69611.21661.01765.39215.75
Short Term Receivables19.3616.293.702.483.041.09
Inventories11.410.000.000.000.000.00
Other Current Assets11.547.271.523.823.640.91
Total Current Assets571.52526.25616.43667.32772.07217.76
Net Property, Plant & Equipment4.482.994.324.683.660.69
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets11.214.62-0.000.000.00
Other Assets7.616.760.730.140.423.35
Total Assets594.82540.63621.48672.14776.15221.79
Short Term Debt Incl. Current Port. of LT Debt17.197.951.971.210.860.00
Accounts Payable9.486.352.212.143.922.17
Income Tax Payable0.290.68----
Other Current Liabilities55.2843.279.799.8212.144.38
Total Current Liabilities82.2358.2413.9713.1616.936.55
Long Term Debt195.570.972.043.052.190.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities11.3017.620.350.8511.040.16
Total Liabilities289.1176.8416.3617.0730.156.71
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity305.72463.79605.12655.08746.00215.08
Total Shareholders Equity305.72463.79605.12655.08746.00215.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity305.72463.79605.12655.08746.00215.08
Total Liabilities & Stockholders Equity594.82540.63621.48672.14776.15221.79
Book Value Per Share0.901.372.763.003.421.44
Tangible Book Value Per Share0.871.362.763.003.421.44
Full-Time Employees29822051536436
Price to Book Ratio6.641.780.540.632.481.81
Return on Assets-36.04-97.74-11.72-14.39-18.86-
Return on Equity-53.18-106.27-12.03-14.87-20.07-
Return on Invested Capital-40.82-122.20-12.48-15.83-11.61-19.37
Quick Ratio6.819.0444.1150.7045.6233.24
Current Ratio6.959.0444.1150.7045.6233.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-135.93-204.63-567.94-75.80-104.20-86.85-41.66
Depreciation2.191.740.680.220.480.370.10
Other Funds (Non Cash)61.9141.44449.357.0411.0513.502.92
Funds from Operations-71.83-161.45-117.91-68.54-92.66-72.98-38.64
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-34.36-11.98-12.510.54-3.454.792.11
Cash from Operating Activities-106.19-173.43-130.41-68.00-96.11-68.19-36.53
Capital Expenditures-1.98-8.35-0.16-0.07-0.37-0.28-0.14
Net Assets From Acquisitions0.000.00-7.430.000.000.000.00
Sale of Fixed Assets and Businesses0.000.0019.860.010.010.000.00
Purchase or Sale of Investments-57.93107.87110.448.9863.81-454.39-72.68
Purchase of Investments-420.63-354.42-339.64-703.37-520.31-609.30-143.29
Sale Or Maturity of Investments362.70462.29450.08712.35584.12154.9170.61
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.002.51
Cash from Investing Activities-59.9199.52122.708.9263.46-454.67-70.32
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock22.0911.424.880.631.33625.53135.66
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock22.0911.424.880.631.33625.53135.66
Proceedsfrom Stock Options0.000.000.000.000.00624.77135.66
Issuance or Reduction of Debt, Net199.71191.11-4.550.000.000.000.00
Change in Long Term Debt199.71191.110.000.000.000.000.00
Issuance of Long Term Debt290.32203.510.000.000.000.000.00
Reduction of Long Term Debt-90.60-12.390.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-2.52
Other Financing Activities Uses0.000.000.000.000.000.00-2.52
Cash from Financing Activities221.80202.530.330.631.33625.53133.13
Exchange Rate Effect-0.83-0.270.45----
Net Change in Cash54.87128.36-6.93-58.45-31.32102.6726.29
Free Cash Flow-108.17-173.78-130.57-68.07-96.48-68.47-36.67
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments663.37660.96533.73529.21549.04607.72
Short Term Receivables40.2231.7125.9819.3613.856.68
Inventories15.3419.9015.8411.415.710.55
Other Current Assets15.7313.8615.9711.548.938.26
Total Current Assets734.66726.43591.53571.52577.53623.21
Net Property, Plant & Equipment16.413.964.134.484.895.26
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets19.8010.2910.7611.2111.6812.14
Other Assets7.523.823.827.617.466.62
Total Assets778.39744.50610.24594.82601.56647.23
Short Term Debt Incl. Current Port. of LT Debt22.9120.6115.5717.1913.4710.21
Accounts Payable9.4512.0922.439.4815.3622.42
Income Tax Payable---0.29--
Other Current Liabilities66.2054.0641.5255.2839.3033.72
Total Current Liabilities98.5686.7579.5282.2368.1366.36
Long Term Debt445.21395.66201.41195.57194.68193.15
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.658.239.7411.3012.8714.81
Total Liabilities550.42490.64290.68289.11275.68274.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity227.97253.86319.56305.72325.88372.91
Total Shareholders Equity227.97253.86319.56305.72325.88372.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity227.97253.86319.56305.72325.88372.91
Total Liabilities & Stockholders Equity778.39744.50610.24594.82601.56647.23
Book Value Per Share0.650.730.920.900.951.10
Tangible Book Value Per Share0.590.700.890.870.921.07
Full-Time Employees310--298291-
Price to Book Ratio6.646.164.749.423.351.58
Return on Assets-19.70-21.53-26.48-36.04-37.08-32.67
Return on Equity-49.09-47.81-39.51-53.18-52.49-64.40
Return on Invested Capital-6.22-9.671.04-7.30-10.72-10.42
Quick Ratio7.308.147.246.818.399.38
Current Ratio7.458.377.446.958.489.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-41.90-62.845.40-36.59-55.79-59.01
Depreciation0.580.540.540.540.530.36
Other Funds (Non Cash)14.2924.4010.6312.6011.03-2.02
Funds from Operations-27.04-37.9116.57-23.46-44.23-60.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-11.53-5.06-11.50-6.28-8.6612.49
Cash from Operating Activities-38.56-42.975.07-29.73-52.89-48.18
Capital Expenditures-1.59-0.25-0.05-0.09-8.01-0.18
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-107.766.24-43.5987.17-88.6155.06
Purchase of Investments-225.88-67.69-82.15-44.90-167.14-81.67
Sale Or Maturity of Investments118.1373.9438.56132.0778.53136.73
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-109.345.99-43.6487.08-96.6254.88
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.954.750.918.490.561.29
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.954.750.918.490.561.29
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net35.22165.78-0.86-0.42-6.66198.74
Change in Long Term Debt35.22165.78-0.86-0.42191.540.00
Issuance of Long Term Debt36.49242.620.0011.20192.310.00
Reduction of Long Term Debt-1.27-76.84-0.86-11.62-0.770.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities43.16170.530.048.060.50193.42
Exchange Rate Effect-0.10-0.34-0.17-0.22-0.06-0.13
Net Change in Cash-104.84133.21-38.7065.19-149.07199.99
Free Cash Flow-40.15-43.225.02-29.82-52.90-48.36

Revenue breakdown

Consolidation, Policy2025: -37.00K
License2024: 7.87M 2025: 38.24M
Product2025: 24.70M
China2024: 5.15M 2025: 9.40M
Consolidation, Policy2025: 2.00K
Japan2024: 2.73M 2025: 28.80M
United States2025: 24.70M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.47%62.0M253.3M5.35M
2026-10-1525.09%63.2M252.0M5.56M
2026-09-3023.36%58.9M252.0M5.61M
2026-09-1523.09%58.2M252.0M6.82M
2026-08-3121.54%54.3M252.0M6.75M
2026-08-1421.19%53.2M251.2M6.63M
2026-07-3120.89%53.4M255.7M6.45M
2026-07-1521.95%55.7M253.6M6.06M
2026-06-3021.43%54.4M253.6M5.35M
2026-06-1519.29%48.9M253.6M4.05M
2026-05-2921.72%53.7M247.1M4.33M
2026-05-1520.84%51.5M247.1M4.41M
2026-04-3020.59%50.6M245.8M4.37M
2026-04-1520.64%50.3M243.6M4.70M
2026-03-3120.00%48.7M243.6M5.41M
2026-03-1320.30%49.5M243.6M5.78M
2026-02-2719.23%46.9M243.6M5.65M
2026-02-1320.26%48.8M241.0M7.26M
2026-01-3020.44%48.9M239.4M7.71M
2026-01-1520.03%48.0M239.4M8.44M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.402.152.295.10054.000.000.856-0.0710.002
call5.000.000.100.051.1352,68025.000.240-0.0140.002
call7.500.000.050.042.2662,1611.000.082-0.0130.001
call10.000.000.750.003.1120.000.000.066-0.0150.001
put2.500.000.950.008.2450.000.00-0.144-0.0700.002
put5.000.550.850.621.3724,74310.00-0.767-0.0130.002
put7.502.553.802.785.0181.000.00-0.918-0.0120.001
put10.005.106.305.306.1030.000.00-0.934-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-068-KCurrent report2026-06-30SEC
2026-06-308-KCurrent report2026-06-24SEC
2026-06-29424B5SEC
2026-06-29305B2Application for designation of a new trustee under the Trust Indenture ActSEC
2026-06-26FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-06-25424B5SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-05-278-KCurrent report2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264/A2026-02-27SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800709.24K1
2026-070000
2026-06118.25K11.42M3
2026-050000
2026-04001.34M3
2026-030000
2026-020000
2026-010000
2025-12001.17M1
2025-11004.54M7

Institutional holders

Manager% owned
FMR LLC14.96%
BlackRock, Inc.7.91%
Decheng Capital LLC7.43%
VANGUARD CAPITAL MANAGEMENT LLC3.41%
Omega Fund Management, LLC2.31%
Laurion Capital Management LP2.19%
STATE STREET CORP2.11%
GEODE CAPITAL MANAGEMENT, LLC1.83%
ABSOLUTE INVESTMENT ADVISERS, LLC1.56%
Duquesne Family Office LLC1.30%

Funds

Fund% owned
Fidelity Growth Company Fund5.03%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.53%
iShares Russell 2000 ETF1.88%
iShares Convertible Bond ETF1.47%
Fidelity Growth Company K6 Fund1.42%
Fidelity Series Growth Company Fund1.30%
Small Cap Growth Fund0.98%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Fidelity Small Cap Index Fund0.79%
Miller Market Neutral Income Fund0.75%

OakChart. NUVB. Cached 15 minutes.